ALT Past Earnings Q&A
What was the best and worst ALT past earnings results?
For Altimmune, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
The highest ALT past earnings result in our data set was -0.02/share posted in Q4 2018, while the lowest was in Q3 2018 when ALT posted -1.73/share.
The biggest top line earnings performance — aka revenue — quarter was in Q4 2021 when ALT reported 0.00B in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at 0.00M of revenue.
There are 20 ALT past earnings results in our data set.
On this page we presented the ALT past earnings date information for Altimmune. Reviewing that
ALT Past Earnings
for the company, we see that the highest past earnings result in our data set was in Q4 2018, when ALT posted gaap of -0.02/share. Meanwhile the lowest ALT past earnings result was in Q3 2018, when ALT posted gaap of -1.73/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2021 when ALT reported 0.00B in revenue, while the smallest revenue quarter was Q3 2022 when ALT reported 0.00M in revenue.
Any self directed investor doing their due diligence on ALT or any other given stock can benefit from
researching all of the Altimmune past earnings — and here, we present each quarter's result all together
on one page for easy comparison. Studying this information can help when projecting future earnings, as well
as determining whether the past earnings trajectory justifies the current stock value.
That's why we bring you PastEarnings
.com to make it easy for investors to investigate
Altimmune past earnings, or the past earnings information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for ALT. Thanks for visiting, and the next
time you need to research ALT past earnings
or those of another stock, we hope you'll think of our site, as your
go-to past earnings research resource of choice.